Tyra Biosciences Posts 74c Quarterly Loss, Cash of $700.5M
TYRA sits 61% above its 52-week low of $13.83.
Summary
Tyra reported a third-quarter net loss of $51.1 million, or 74 cents a share, with R&D spending rising. The company ended the period with $700.5 million in cash and securities, a cushion built largely on the $400 million offering priced at $22.03 a share in September. That balance is the key number here: it funds the dabogratinib bladder cancer program well past the current readouts, so the loss itself is not a liquidity concern. The stock trades near the offering price, so the quarter's cash burn rate is what matters for any future raise. The 8-K filed at 13:03 ET carries the same figures.
At the time of this announcement, TYRA was trading at $22.25 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $13.83 to $40.65. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.